Canntab Therapeutics aims to deliver more precise, easy-to-take THC and CBD via its pills proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
News provided by
Share this article
Company or
Canntab ), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce the Canadian Intellectual Property Office (
CIPO ) has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations with a priority date of January 23, 2017. The term of the patent expires on January 22, 2038.
Canntab s Legal Counsel on intellectual property, Gavin Bogle of Magyar, Bogle & O Hara LLP said, The allowance of Canntab s patent by the Canadian Intellectual Property Office provides fundamental intellectual protection for Canntab s innovative tableting technology and validates the years of research and development the company has conducted. The Company now has patent protection in Canada and the USA providing an international scope to the Company s expanding